{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.7","upperLimit":"4.8","value":"3.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"description":"PFS is defined as the time from the first dose of cross-over therapy to the first documented occurrence of PD or death. PFS was summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to chemotherapy and who did not receive subsequent anti-cancer therapy after discontinuing chemotherapy were allowed to cross-over to Trametinib and received 2 mg tablet once daily until disease progression, death or withdrawal.","id":"OG000","title":"Cross-over From Chemotherapy to Trametinib"}],"paramType":"MEDIAN","populationDescription":"Cross-over Population","reportingStatus":"POSTED","timeFrame":"Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)","title":"PFS Following Cross-over to Trametinib as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"Months"}